<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-377 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-377</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-377</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-7.html">extraction-schema-7</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of population differences in the prevalence of activating EGFR mutations in lung cancer and proposed reasons for higher frequency in East Asians. Include quantitative evidence about mutation frequencies by ancestry, smoking status, sex, and age; germline variants and their allele frequencies/associations; environmental and hormonal exposures; mutational signatures and tumor mutation burden; co-mutation patterns; and differential response to EGFR-TKIs by ethnicity. Capture study design, methods, and any counter-evidence or limitations.</div>
                <p><strong>Paper ID:</strong> paper-15165056</p>
                <p><strong>Paper Title:</strong> <a href="ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/e4/33/J_Korean_Med_Sci_2009_Jun_12_24(3)_448-452.tar.gz" target="_blank">Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung</a></p>
                <p><strong>Paper Abstract:</strong> Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) have been reported to be related to certain clinical characteristics (i.e., female, non-smokers with adenocarcinoma) and gefitinib responsiveness. This exploratory analysis was performed to determine the incidence of EGFR mutations in male smokers with squamous cell carcinoma, who were treated with EGFR tyrosine kinase inhibitor, gefitinib. Sixty-nine Korean NSCLC patients were treated with gefitinib in a prospective study. For a subset of 20 male patients with squamous cell carcinoma and a history of smoking, pretreatment tumor tissue samples were obtained and analyzed for EGFR mutations (exons 18 to 21). EGFR mutations were found in 3 (15%) patients, including in-frame deletions within exon 19 (n=2) and L858R missence mutation in exon 21 (n=1). These 3 patients with EGFR mutations responded to gefitinib, whereas only one of remaining 17 patients with wild-type EGFR achieved clinical response. Trend toward longer progression-free (5.8 vs. 2.4 months; P=0.07) was noted in patients with EGFR mutations compared to those with wild-type EGFR. Although male smokers with squamous cell carcinoma have not been considered ideal candidates for gefitinib treatment, significant incidence of EGFR mutations was observed. The molecular markers should be considered to predict clinical benefits from gefitinib.</p>
                <p><strong>Cost:</strong> 0.011</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e377.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e377.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of population differences in the prevalence of activating EGFR mutations in lung cancer and proposed reasons for higher frequency in East Asians. Include quantitative evidence about mutation frequencies by ancestry, smoking status, sex, and age; germline variants and their allele frequencies/associations; environmental and hormonal exposures; mutational signatures and tumor mutation burden; co-mutation patterns; and differential response to EGFR-TKIs by ethnicity. Capture study design, methods, and any counter-evidence or limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR-activating mutations (Korean male smokers, SCC)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Activating epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations in Korean male smokers with squamous cell carcinoma of the lung</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Retrospective molecular analysis (exons 18-21 by PCR and Sanger sequencing) of 20 Korean male smokers with squamous cell carcinoma treated with gefitinib; found activating EGFR mutations in 3/20 (15%) with exon 19 deletions (n=2) and L858R (exon 21, n=1), and these mutation-positive patients had objective responses to gefitinib.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>10.3346/jkms.2009.24.3.448</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung</td>
                        </tr>
                        <tr>
                            <td><strong>publication_year</strong></td>
                            <td>2009</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Retrospective exploratory analysis of a subset drawn from a prospective phase II clinical trial (gefitinib-treated advanced NSCLC patients); molecular sequencing of EGFR exons 18-21 on FFPE tumor samples.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_context</strong></td>
                            <td>Korea (single-center, Gil Medical Center / Sungkyunkwan University Samsung Medical Center / Gachon University Gil Medical Center); patients enrolled in a prospective phase II gefitinib clinical trial.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_histology</strong></td>
                            <td>Squamous cell carcinoma of the lung (subset of advanced NSCLC patients); all analyzed patients were male smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_tumor</strong></td>
                            <td>20</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry_groups</strong></td>
                            <td>East Asian (Korean) patients only; ancestry assigned by nationality/clinical recruitment (not by genetic ancestry inference); no direct comparison groups within this study.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency_overall</strong></td>
                            <td>15% (3 of 20 tumors harbored activating EGFR mutations: 3/20 = 15.0%).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency_by_group</strong></td>
                            <td>Within this study only one group: male smokers with squamous cell carcinoma (Korean): 3/20 (15%); by mutation status and response: 3/3 (100%) of EGFR-mutant patients had objective responses to gefitinib vs 1/17 (5.9%) of wild-type EGFR patients (P < 0.01). Median PFS: EGFR-mutant 5.8 months vs wild-type 2.4 months (P = 0.07, trend but not statistically significant). Overall OS similar (9.6 vs 7.2 months; P = 0.76). The paper does not provide stratified frequencies by ancestry (other than citing literature), sex (all male), age strata, or separate smoking-status strata (all were current or former smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>effect_size_ethnic_difference</strong></td>
                            <td>Not reported in this study (no internal ethnic comparison; only qualitative references to higher frequency in Asians in prior literature).</td>
                        </tr>
                        <tr>
                            <td><strong>difference_persists_in_never_smokers</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>difference_persists_after_adjustment</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_subtypes_distribution</strong></td>
                            <td>Of 3 activating mutations: exon 19 in-frame deletions n = 2 (66.7%), exon 21 L858R n = 1 (33.3%); no other subtypes (G719X, L861Q, exon 20 insertions) reported in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>co_mutation_landscape</strong></td>
                            <td>Not reported (no data on TP53, KRAS, STK11, KEAP1 or other co-mutations in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_spectrum</strong></td>
                            <td>Not reported (no TMB values or base-substitution spectra provided).</td>
                        </tr>
                        <tr>
                            <td><strong>mutational_signatures</strong></td>
                            <td>Not reported (no COSMIC signature analysis).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_exposures_assessed</strong></td>
                            <td>Smoking history recorded (all patients were current or former smokers). No other environmental exposures (e.g., cooking oil fumes, indoor coal, PM2.5, radon, occupational exposures, TB scars) were assessed or analyzed for association with EGFR-mutant status in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>hormonal_factors</strong></td>
                            <td>Not assessed in this study. The paper discusses in background that EGFR mutations have been associated in prior reports with female sex and never-smoking status, but provides no hormonal data or analyses (e.g., estrogen exposure or ER expression) here.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_variants_and_haplotypes</strong></td>
                            <td>Not reported (no germline genotyping or allele frequencies presented).</td>
                        </tr>
                        <tr>
                            <td><strong>inherited_egfr_pathogenic_variants</strong></td>
                            <td>Not reported (no data on germline T790M or other inherited EGFR variants).</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>Not reported / not tested in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>testing_or_selection_bias</strong></td>
                            <td>Several potential biases are noted by the authors: analysis is retrospective on a subset (20/69 patients) whose paraffin tumor blocks were available; small sample size and few mutations limit statistical power; patients were selected from a prospective clinical trial and had unfavorable clinical characteristics (advanced, pretreated), which may reduce generalizability; authors note methods for mutation detection were consistent with prior reports but there is no universally approved method (possible methodological heterogeneity across studies); authors state there was no significant difference in survival between patients with and without EGFR mutation data at time of analysis (attempt to address selection), but otherwise potential referral/case-mix and sample-availability biases remain.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_tki_response_by_ethnicity</strong></td>
                            <td>This paper reports that in their Korean cohort the 3 EGFR-mutant patients (all Korean) had objective responses to gefitinib (3/3), while only 1/17 wild-type patients responded (P < 0.01). The study does not perform cross-ethnic comparisons; it cites prior multicenter trials (ISEL, erlotinib phase III) in which Asian subsets and never-smoker subsets showed greater survival benefit, but no ethnicity-adjusted effect sizes from this cohort are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>methods_key_details</strong></td>
                            <td>Tumor DNA extracted from 5 x 10 Î¼m FFPE sections using QIAamp DNA Mini kit; PCR amplification of EGFR exons 18-21 with specified primer sequences and PCR conditions; PCR products gel-purified (Qiagen) and Sanger-sequenced using ABI PRISM BigDye v3.1 and ABI PRISM 3100 Analyzer; sequence analysis with Sequencer 3.1.1. Mutation detection followed methods in refs (11,12). Statistical analyses: chi-square for response vs mutation, Kaplan-Meier for PFS/OS, log-rank test for comparisons; P < 0.05 considered significant.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>The paper does not propose new mechanistic explanations for higher EGFR mutation prevalence in East Asians; it reiterates prior observations that EGFR-activating mutations are more frequent in patients with favorable clinical factors (female sex, never-smokers, adenocarcinoma) and more common in patients of Asian origin, but states uncertainty whether improved outcomes are due to therapy or underlying tumor biology and emphasizes using molecular markers (mutation testing) rather than clinical characteristics alone to select patients.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_null_results</strong></td>
                            <td>Authors note their observed incidence (15%) is consistent with some Western and other Korean data but lower than frequencies reported in Taiwan and Japan, indicating geographic/series variability; they also note that EGFR mutation presence does not uniformly predict survival benefit across all trials (predicting survival was not apparent in some phase II/III studies), and that EGFR mutations identify only a fraction of patients who derive benefit from EGFR-TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_conflicts</strong></td>
                            <td>Limitations: small sample size (n=20), retrospective subset analysis, limited power due to few mutation events, selected population (third-line gefitinib-treated, advanced disease), all patients male smokers with squamous histology (limits generalizability), lack of broader molecular profiling and ancestry comparisons. Conflicts/funding: study supported in part by an unrestricted educational grant from Sanofi-Aventis Korea; no other conflicts of interest explicitly stated in the text provided.</td>
                        </tr>
                        <tr>
                            <td><strong>notable_quotes</strong></td>
                            <td>"These EGFR mutations have been known to be found more frequently in patients of an Asian origin and associated with improved survival in these patients." (Discussion) "In the Iressa Survival Evaluation in Lung Cancer (ISEL) trial ... subsets of never-smokers and Asian patients had a significant survival benefit." (Discussion)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung', 'publication_date_yy_mm': '2009-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. <em>(Rating: 2)</em></li>
                <li>Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). <em>(Rating: 2)</em></li>
                <li>Erlotinib in lung cancer-molecular and clinical predictors of outcome. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>